|
|
Postgrad Med J. 1980 July; 56(657): 481–484. | PMCID: PMC2425807 |
Growth hormone, prolactin and thyrotrophin responses to thyrotrophin-releasing hormone in diabetic patients. A. D. Harrower Abstract Growth hormone (GH), prolactin (PRL) and thyrotrophin (TSH) responses to thyrotrophin-releasing hormone (TRH) were studied in 15 insulin-dependent diabetic patients. Basal plasma GH levels were raised above 5 mu./l in 6 patients and following the injection of TRH there was a significant rise in plasma GH levels in 9. The mean rise in plasma GH from basal to peak values was significant in the group as a whole (P < 0.01). Basal PRL and TSH levels were normal and rose normally in response to TRH. GH release may be qualitatively abnormal in some diabetics and any such loss of specificity of GH-releasing mechanisms would further contribute to the raised GH levels found in many diabetics which would be of importance if GH is a factor in the aetiology of diabetic microangiopathy. Full text Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (501K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References. These references are in PubMed. This may not be the complete list of references from this article. - Corrall RJ, Hunter WM, Campbell IW, Harrower AD, Duncan LJ, Clarke BF. Reversal by insulin treatment of abnormal growth hormone pattern in newly diagnosed diabetes mellitus. Acta Endocrinol (Copenh). 1974 Sep;77(1):115–121. [PubMed]
- Cullen JF, Gibson PF, Maccuish AC, Harris P, Donaldson AA, Munro JF, Duncan LJ. Pituitary gland ablation by 90yttrium implantation for advancing diabetic retinopathy. A further report. Br J Ophthalmol. 1971 Apr;55(4):217–224. [PubMed]
- Czernichow P, Dauzet MC, Broyer M, Rappaport R. Abnormal TSH, PRL and GH response to TSH releasing factor in chronic renal failure. J Clin Endocrinol Metab. 1976 Sep;43(3):630–637. [PubMed]
- Gomez-Pan A, Tunbridge WM, Duns A, Hall R, Besser GM, Coy DH, Schally AV, Kastin AJ. Hypothalamic hormone interaction in acromegaly. Clin Endocrinol (Oxf). 1975 Sep;4(5):455–460. [PubMed]
- Gonzalez-Barcena D, Kastin AJ, Schalch DS, Torres-Zamora M, Perez-Pasten E, Kato A, Schally AV. Responses to thyrotropin-releasing hormone in patients with renal failure and after infusion in normal men. J Clin Endocrinol Metab. 1973 Jan;36(1):117–120. [PubMed]
- Hansen AP. Abnormal serum growth hormone response to exercise in juvenile diabetics. J Clin Invest. 1970 Aug;49(8):1467–1478. [PubMed]
- Hansen AP. Normalization of growth hormone hyperresponse to exercise in juvenile diabetics after "normalization" of blood sugar. J Clin Invest. 1971 Sep;50(9):1806–1811. [PubMed]
- Hansen AP, Johansen K. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. Diabetologia. 1970 Feb;6(1):27–33. [PubMed]
- Harrower AD, Yap PL, Nairn IM, Walton HJ, Strong JA, Craig A. Growth hormone, insulin, and prolactin secretion in anorexia nervosa and obesity during bromocriptine treatment. Br Med J. 1977 Jul 16;2(6080):156–159. [PubMed]
- Irie M, Tsushima T. Increase of serum growth hormone concentration following thyrotropin-releasing hormone injection in patients with acromegaly or gigantism. J Clin Endocrinol Metab. 1972 Jul;35(1):97–100. [PubMed]
- Irvine WJ, Toft AD, Hunter WM, Kirkham KE. An assessment of plasma TSH radioimmunoassay and of the TSH stimulation test in the diagnosis of 100 consecutive patients with suspected hypothyroidism. Clin Endocrinol (Oxf). 1973 Apr;2(2):135–139. [PubMed]
- Joplin GF, Fraser R, Hill DW, Oakley NW, Scott DJ, Doyle Pituitary ablation for diabetic retinopathy. Q J Med. 1965 Oct;34(136):443–462. [PubMed]
- Kohner EM, Hamilton AM, Joplin GF, Fraser TR. Florid diabetic retinopathy and its response to treatment by photocoagulation or pituitary ablation. Diabetes. 1976 Feb;25(2):104–110. [PubMed]
- LUFT R, OLIVECRONA H, SJOGREN B. Hypophysectomy in man: experiences in severe diabetes mellitus. J Clin Endocrinol Metab. 1955 Apr;15(4):391–408. [PubMed]
- Liuzzi A, Chiodini PG, Botalla L, Silvestrini F, Müller EE. Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: homogeneity in the two responses. J Clin Endocrinol Metab. 1974 Nov;39(5):871–876. [PubMed]
- Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R. Diabetes, diabetic angiopathy, and growth hormone. Lancet. 1970 Jul 18;2(7664):131–133. [PubMed]
- Lundbaek K, Christensen NJ, Jensen VA, Johansen K, Olsen TS, Hansen AP, Orskov H, Osterby R. The pathogenesis of diabetic angiopathy and growth hormone. Dan Med Bull. 1971 Feb;18(1):1–7. [PubMed]
- Passa P, Rousselie F, Gauville C, Canivet J. Retinopathy and plasma growth hormone levels in idiopathic hemochromatosis with diabetes. Diabetes. 1977 Feb;26(2):113–120. [PubMed]
- Ray BS, Pazianos AG, Greenberg E, Peretz WL, McLean JM. Pituitary ablation for diabetic retinopathy. I. Results of hypophysectomy. (A ten-year evaluation). JAMA. 1968 Jan 8;203(2):79–84. [PubMed]
- Reuter AM, Kennes F, Gevaert Y, Franchimont P. Homologous radioimmunoassay for human prolactin. Int J Nucl Med Biol. 1976 Jan;3(1):21–28. [PubMed]
- SCHALCH DS, PARKER ML. A SENSITIVE DOUBLE ANTIBODY IMMUNOASSAY FOR HUMAN GROWTH HORMONE IN PLASMA. Nature. 1964 Sep 12;203:1141–1142. [PubMed]
|
This article has been